Volume Spike Investor

Human Genome Sciences Inc. (NASDAQ: HGSI) is trading lower after it and GlaxoSmithKline (NYSE: GSK) announced topline 76-week results of the Phase III BLISS-76 trial of Benlysta in Systemic Lupus Erythematosus…  BENLYSTA already met its primary efficacy endpoint at Week 52 in both BLISS-52 and BLISS-76 studies in July and November 2009; at Week 76 [...]

The bull market is officially one-year old now.  March 9, 2009 was the absolute low for the index levels.  VSInvestor.com has pulled many of biggest stock movers from the Russell 2000 Index.  Amazingly, we had to include stocks which up a whopping 800% just to get the list down to close to 40 stocks.  This [...]

Human Genome Sciences (NASDAQ: HGSI) is trading up 2.6% at $28.25 this morning on an analyst call that is getting surprisingly very little coverage so far when you consider the move this stock has seen.  The biotech and genomics player was started as “Outperform” at RBC Capital with a $38 price target.  The highest target [...]

Human Genome Sciences, Inc. (NASDAQ: HGSI) has raised its stock offering due to strong demand.  The company sold 15,500,000 new shares of common stock at $26.75 per share after a $27.46 closing bell price Wednesday. The size of the offering was increased from 12,500,000 shares.  Net proceeds from the offering are now estimated at approximately [...]

Human Genome Sciences, Inc. (NASDAQ: HGSI) announced a secondary offering last night of up to 12.5 million shares.  This now looks further and further as though it is dwindling as a takeover candidate.  This would raise over $300 million.  It is safe to assume that trading volume will pick up as we get closer to [...]

Human Genome Sciences Inc. (NASDAQ: HGSI) was lower this morning and had been off our radar as a result after yesterday’s huge moves.  Yet at 1:30 PM EST we have just hit the virtual double on average daily volume.  Shares are up 8% at $27.34 on about 16.2 million shares versus and average volume of [...]

Human Genome Sciences, Inc. (NASDAQ: HGSI) is soaring after its expected study results showed that its second round of Phase II data showed that the Benlysta lupus drug was very effective at higher doses.  The lower doses did not show as much improvement, although this is due to the notion that there have been no [...]

Human Genome Sciences, Inc.  (NASDAQ: HGSI) has been soaring today.  At 2:45 PM EST we saw this one already cross a full day’s trading volume at 120% normal stock trading volume and that options were picking up throughout the day.  This follows the JPMorgan upgrade to Overweight from Neutral ahead of new additional clinical data.  [...]

Human Genome Sciences Inc. (NASDAQ: HGSI) is trading higher this morning, and it doesn’t seem to be tied to those pesky buyout or merger rumors that were persisting for a couple of weeks.  The company announced that a medical journal published positive comments concerning its lupus drug candidate, which may be like reporting from the [...]

Human Genome Sciences, Inc. (NASDAQ: HGSI) is getting clipped this morning as the hopes of the buyout settle down on the realization that large drug companies might not want to pay up over and above a more than tenfold rise in shares.  HGSI is down almsot 3% at $19.32 on about 30,000 shares as of [...]